Explore journal overview, editorial leadership, indexing, articles in press, latest published work, and highlights from previous issues.
Anti-obesity medication/weight loss drugs are pharmacological agents which reduce to control weight. The main treatment for overweight and obese to do regular dieting and physical exercise.
Anti-obesity medication drugs alter one of the fundamental processes of the body, weight regulation, by altering either appetite or absorption of calories.
Iorlistat (Xenical) is currently approved by the FDA for long-term use as it reduces intestinal fat absorption by inhibiting pancreatic lipase.
Rimonabant
(Acomplia) works by specific blockage of the endocannabinoid system. Sibutramine
(Meridia) which inhibit deactivation of the neurotransmitters, thereby
decreasing appetite in the brain.
Journal of Obesity
and Diabetes emphasize in publishing the original scholarly articles
related to Obesity and Diabetes worldwide. The journal follows rapid review
process with the Eminent Editorial Board
Researchers, authors, reviewers, and readers can use this page to find journal resources connected with Anti-obesity medication, including published articles, related academic topics, current issue content, archive material, and manuscript submission information.
Related article links for Anti-obesity medication will appear here as matching content is published in Journal of Obesity and Diabetes (ISSN: 2638-812X). Readers can also browse the journal archive and current issue for connected research.
